Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Практическая пульмонология (ранее – "Атмосфера. Пульмонология и аллергология"): ISSN 2409-756X (Online), ISSN 2409-6636 (Print)
2021 / N 2

Перспективы применения N-ацетилцистеина у пациентов с длительными респираторными симптомами пост-COVID-19: данные научной литературы и собственный клинический опыт
Л.Я. Французевич, А.П. Бобков, Ф.А. Петряйкин, Н.Ю. Кравченко, Т.Н. Краснова, А.С. Белевский

References

1. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. NICE guideline [NG188]. Published: 18 Dec 2020. Last updated: 11 Nov 2021. Available from: https://www.nice.org.uk/guidance/ng188 Accessed 2022 Jan 17.
2. Datta SD, Talwar A, Lee JT. A proposed framework and timeline of the spectrum of disease due to SARS-CoV-2 infection: illness beyond acute infection and public health implications. JAMA 2020 Nov;324(22):2251-2.
3. Raman B, Cassar MP, Tunnicliffe EM, Filippini N, Griffanti L, Alfaro-Almagro F, Okell T, Sheerin F, Xie C, Mahmod M, Mózes FE, Lewandowski AJ, Ohuma EO, Holdsworth D, Lamlum H, Woodman MJ, Krasopoulos C, Mills R, McConnell FAK, Wang C, Arthofer C, Lange FJ, Andersson J, Jenkinson M, Antoniades C, Channon KM, Shanmuganathan M, Ferreira VM, Piechnik SK, Klenerman P, Brightling C, Talbot NP, Petousi N, Rahman NM, Ho LP, Saunders K, Geddes JR, Harrison PJ, Pattinson K, Rowland MJ, Angus BJ, Gleeson F, Pavlides M, Koychev I, Miller KL, Mackay C, Jezzard P, Smith SM, Neubauer S. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. EClinicalMedicine 2021 Jan 7;31:100683.
4. Sollini M, Ciccarelli M, Cecconi M, Aghemo A, Morelli P, Gelardi F, Chiti A. Vasculitis changes in COVID-19 survivors with persistent symptoms: an [18F]FDG-PET/CT study. European Journal of Nuclear Medicine and Molecular Imaging 2021 May;48(5):1460-6.
5. Dennis A, Wamil M, Kapur S, Alberts J, Badley AD, Decker GA, Rizza SA, Banerjee R, Banerjee A. Multi-organ impairment in low-risk individuals with long COVID. medRxiv 2020.10.14.20212555. Posted Oct 16 2020. doi: https://doi.org/10.1101/2020.10.14.20212555.
6. Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, Li P, Hu B, Wang J, Hu C, Jin Y, Niu X, Ping R, Du Y, Li T, Xu G, Hu Q, Tu L. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. The American Journal of Gastroenterology 2020 May;115(5):766-73.
7. Mandal S, Barnett J, Brill SE, Brown JS, Denneny EK, Hare SS, Heightman M, Hillman TE, Jacob J, Jarvis HC, Lipman MCI, Naidu SB, Nair A, Porter JC, Tomlinson GS, Hurst JR; ARC Study Group. ‘Long-COVID’: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax 2021 Apr;76(4):396-8.
8. Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, Walshaw C, Kemp S, Corrado J, Singh R, Collins T, O’Connor RJ, Sivan M. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. Journal of Medical Virology 2021 Feb;93(2):1013-22.
9. Goërtz YMJ, Van Herck M, Delbressine JM, Vaes AW, Meys R, Machado FVC, Houben-Wilke S, Burtin C, Posthuma R, Franssen FME, van Loon N, Hajian B, Spies Y, Vijlbrief H, van ‘t Hul AJ, Janssen DJA, Spruit MA. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Research 2020 Oct;6(4):00542-2020.
10. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, Kang L, Guo L, Liu M, Zhou X, Luo J, Huang Z, Tu S, Zhao Y, Chen L, Xu D, Li Y, Li C, Peng L, Li Y, Xie W, Cui D, Shang L, Fan G, Xu J, Wang G, Wang Y, Zhong J, Wang C, Wang J, Zhang D, Cao B. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. The Lancet 2021 Jan;397(10270):220-32.
11. Chopra V, Flanders SA, O’Malley M, Malani AN, Prescott HC. Sixty-day outcomes among patients hospitalized with COVID-19. Annals of Internal Medicine 2021 Apr;174(4):576-8.
12. Carfì A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA 2020 Aug;324(6):603-5.
13. Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re’em Y, Redfield S, Austin JP, Akrami A. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 2021 Aug;38:101019.
14. UK Office for National Statistics. Prevalence of long COVID symptoms and COVID-19 complications. 2020. Released date: 16 Dec 2020. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifeexpectancies/datasets/prevalenceoflongcovidsymptomsandcovid19complications Accessed 2022 Jan 17.
15. Crook H, Raza S, Nowell J, Young M, Edison P. Long covid – mechanisms, risk factors, and management. BMJ 2021 Jul;374:n1648.
16. Mo X, Jian W, Su Z, Chen M, Peng H, Peng P, Lei C, Chen R, Zhong N, Li S. Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. The European Respiratory Journal 2020 Jun 18;55(6):2001217.
17. Menicagli R, Limodio M, Limodio M, Casotti MT, Menicagli L. Pulmonary Covid fibrosis a new pharmaceutic approach. International Journal of Preventive Medicine 2021 Mar;12:35.
18. Zou H, Li SQ. Pulmonary fibrosis in critically ill patients with novel coronavirus pneumonia during the convalescent stage and a proposal for early intervention. Acta Pharmacologica Sinica 2021 Aug;42(8):1376-8.
19. Isidori AM, Giannetta E, Pofi R, Venneri MA, Gianfrilli D, Campolo F, Mastroianni CM, Lenzi A, d’Ettorre G. Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection. The DEDALO project. Andrology 2021 Jan;9(1):33-8.
20. Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7). Wai PF, editor. Chinese Medical Journal (in English) 2020 May;133(9):1087-95.
21. Dal Moro F, Livi U. Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID-19 infections? A lesson from urology. Clinical Immunology (Orlando, Fla) 2020 May;214:108414.
22. Ballester B, Milara J, Cortijo J. Mucins as a new frontier in pulmonary fibrosis. Journal of Clinical Medicine 2019 Sep;8(9):1447.
23. Carson G; Long Covid Forum Group. Research priorities for Long Covid: refined through an international multi-stakeholder forum. BMC Medicine 2021 Mar;19(1):84.
24. World Health Organization. A coordinated global research roadmap. 2019 Novel Coronavirus. 12 March 2020. Available from: https://www.who.int/publications/m/item/a-coordinated-global-research-roadmap Accessed 2022 Jan 17.
25. World Health Organization. COVID-19 clinical management. Living guidance. 25 January 2021. Available from: https://www.portailvasculaire.fr/sites/default/files/docs/2021-01-25_who_covid-19_clinical_management.pdf Accessed 2022 Jan 17.
26. National Institute of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines. 2021. Available from: https://www.covid19treatmentguidelines.nih.gov/ Accessed 2022 Jan 17.
27. CDC. Centers for Disease Control and Prevention. COVID-19. Management of post-COVID conditions: evaluating and caring for patients with post-COVID conditions: interim guidance. Updated June 14, 2021. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-management.html Accessed 2022 Jan 17.
28. Mayo Clinic. COVID-19: advice, updates and vaccines options. Shortness of breath. June 13, 2020. Available from: https://www.mayoclinic.org/symptoms/shortness-of-breath/basics/when-to-see-doctor/sym-20050890 Accessed 2022 Jan 17.
29. Holland AE, Hill CJ, Jones AY, McDonald CF. Breathing exercises for chronic obstructive pulmonary disease. The Cochrane Database of Systematic Reviews 2012 Oct;(10):CD008250.
30. McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. The Cochrane Database of Systematic Reviews 2015 Feb;(2):CD003793.
31. O’Neill S, McCarthy DS. Postural relief of dyspnoea in severe chronic airflow limitation: relationship to respiratory muscle strength. Thorax 1983 Aug;38(8):595-600.
32. Zha L, Xu X, Wang D, Qiao G, Zhuang W, Huang S. Modified rehabilitation exercises for mild cases of COVID-19. Annals of Palliative Medicine 2020 Sep;9(5):3100-6.
33. National Institute for Health and Care Excellence. Idiopathic pulmonary fibrosis in adults: diagnosis and management. Clinical guideline [CG163]. Published: 12 June 2013. Last updated: 23 May 2017. Available from: https://www.nice.org.uk/guidance/cg163 Accessed 2022 Jan 17.
34. Torrisi SE, Kahn N, Vancheri C, Kreuter M. Evolution and treatment of idiopathic pulmonary fibrosis. La Presse Médicale 2020 Jun;49(2):104025.
35. Mondaini N. Phosphodiesterase type 5 inhibitors and COVID-19: are they useful in disease management? The World Journal of Men’s Health 2020 Jul;38(3):254-5.
36. Chowdhury B, Luu AZ, Luu VZ, Kabir MG, Pan Y, Teoh H, Quan A, Sabongui S, Al-Omran M, Bhatt DL, Mazer CD, Connelly KA, Verma S, Hess DA. The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension. Biochemical and Biophysical Research Communications 2020 Mar;524(1):50-6.
37. Aroor AR, Das NA, Carpenter AJ, Habibi J, Jia G, Ramirez-Perez FI, Martinez-Lemus L, Manrique-Acevedo CM, Hayden MR, Duta C, Nistala R, Mayoux E, Padilla J, Chandrasekar B, DeMarco VG. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury. Cardiovascular Diabetology 2018 Jul;17(1):108.
38. Zhang Q, Ju Y, Ma Y, Wang T. N-acetylcysteine improves oxidative stress and inflammatory response in patients with community acquired pneumonia: a randomized controlled trial. Medicine (Baltimore) 2018 Nov;97(45):e13087.
39. Bahrampour Juybari K, Pourhanifeh MH, Hosseinzadeh A, Hemati K, Mehrzadi S. Melatonin potentials against viral infections including COVID-19: current evidence and new findings. Virus Research 2020 Oct;287:198108.
40. Atefi N, Behrangi E, Mozafarpoor S, Seirafianpour F, Peighambari S, Goodarzi A. N-acetylcysteine and coronavirus disease 2019: may it work as a beneficial preventive and adjuvant therapy? A comprehensive review study. Journal of Research in Medical Sciences 2020 Nov;25:109.
41. Ershad M, Naji A, Vearrier D. N-acetylcysteine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019. Last update: June 29 2021. Available from: http://www.ncbi.nlm.nih.gov/books/NBK537183/ Accessed 2022 Jan 17.
42. Hołyńska-Iwan I, Wróblewski M, Olszewska-Słonina D, Tyrakowski T. [The application of N-acetylcysteine in optimization of specific pharmacological therapies]. Polski Merkuriusz Lekarski 2017 Sep;43(255):140-4.
43. Demiralay R, Gürsan N, Erdem H. The effects of erdosteine and N-acetylcysteine on apoptotic and antiapoptotic markers in pulmonary epithelial cells in sepsis. The Eurasian Journal of Medicine 2013 Oct;45(3):167-75.
44. Sun L, Gu L, Wang S, Yuan J, Yang H, Zhu J, Zhang H. N-acetylcysteine protects against apoptosis through modulation of group I metabotropic glutamate receptor activity. PLoS One 2012;7(3):e32503.
45. Liu Y, Liu K, Wang N, Zhang H. N-acetylcysteine induces apoptosis via the mitochondria-dependent pathway but not via endoplasmic reticulum stress in H9c2 cells. Molecular Medicine Reports 2017 Nov;16(5):6626-33.
46. Sancho-Martínez SM, Prieto-García L, Prieto M, Fuentes-Calvo I, López-Novoa JM, Morales AI, Martínez-Salgado C, López-Hernández FJ. N-acetylcysteine transforms necrosis into apoptosis and affords tailored protection from cisplatin cytotoxicity. Toxicology and Applied Pharmacology 2018 Jun;349:83-93.
47. Mata M, Morcillo E, Gimeno C, Cortijo J. N-acetyl-L-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV). Biochemical Pharmacology 2011 Sep;82(5):548-55.
48. Zhang RH, Li CH, Wang CL, Xu MJ, Xu T, Wei D, Liu BJ, Wang GH, Tian SF. N-acetyl-l-cysteine (NAC) protects against H9N2 swine influenza virus-induced acute lung injury. International Immunopharmacology 2014 Sep;22(1):1-8.
49. Hui DS, Lee N, Chan PK, Beigel JH. The role of adjuvant immunomodulatory agents for treatment of severe influenza. Antiviral Research 2018 Feb;150:202-16.
50. Sales AR, Casagrande EM, Hochhegger B, Zanetti G, Marchiori E. The reversed halo sign and COVID-19: possible histopathological mechanisms related to the appearance of this imaging finding. Archivos de Bronconeumolog@ía 2021 Jan;57:73-5. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383165/ Accessed 2022 Jan 17.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]